Coherus BioSciences plans to price its biosimilar of Amgen’s Neulasta, an infection-fighting treatment, at $4,175 per unit, according to Reuters. This is a 33 percent discount off the price of ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Coherus has agreed to sell its biosimilar Udenyca—which references Amgen’s febrile neutropenia drug Neulasta—to Intas Pharmaceuticals for up to $558.4 million. The deal, which is expected to ...

Stimufend ® (pegfilgrastim-fpgk), a biosimilar to Neulasta ® (pegfilgrastim), has been made available by Fresenius Kabi. Stimufend, a leukocyte growth factor, is indicated to decrease the ...

Canada's Apotex filed for approval of a Neulasta biosimilar in December and has also filed for approval of a Neupogen biosimilar that could be on the US market before the end of the year.

Since the Amgen v. Sandoz decision, Amgen and Sandoz have continued to litigate at the trial court level over Sandoz’s biosimilar versions of Neupogen and Neulasta. Based on recent court filings ...

On yesterday’s earnings call for Q4 2016, Amgen indicated that it is projecting its Neulasta® (pegfilgrastim) product to face biosimilar completion in the U.S. by the end of the year.

It’s a lab-created copy of a hormone that’s made naturally by your body. Neulasta is available in biosimilar forms. Biosimilars are like generic drugs. But unlike generics, which are made for ...

Mylan's approval of its Neulasta biosimilar derisks management's 2H guidance and, importantly, demonstrates the company's ability to bring complex generics to market. Fulphila's success will ...

a biosimilar version of Amgen’s Neulasta. Neulasta is the long-acting formulation of Neupogen, listed as filgrastim, which is taken by cancer patients undergoing chemotherapies in order to help ...

Biosimilar pegfilgrastim entered the US market in November 2019; from January to October 2021, the ASP for J2505 declined by 27.9%, whereas the wholesale acquisition cost (WAC) for Neulasta PFS ...

Credit: Getty Images. A biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product. Fylnetra ...